A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.01.26.428251: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources DETAILS: QUANTIFICATION AND STATISTICAL ANALYSIS: Statistical significance was assigned when P values were < 0.05 using Prism Version 8 (GraphPad) GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:We acknowledge …
SciScore for 10.1101/2021.01.26.428251: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources DETAILS: QUANTIFICATION AND STATISTICAL ANALYSIS: Statistical significance was assigned when P values were < 0.05 using Prism Version 8 (GraphPad) GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:We acknowledge several limitations in this study: (a) we did not perform direct immunogenicity and efficacy comparisons with intramuscular delivery of ChAd-SARS-CoV-2; (b) we did not assess durability of immune responses. Future longitudinal studies must be conducted to monitor immune responses over time after intranasal vaccination with ChAd-SARS-CoV-2-S to establish durability; and (c) even with a high dose and invasive route of challenge, many of the control vaccinated animals did not develop severe lung pathology or disease, which limited our ability to conclude protection against disease in this model. In summary, our studies establish that immunization of primates with ChAd-SARS-CoV-2-S induces neutralizing antibody and protective immune responses in both the upper and lower respiratory tract. While several vaccine candidates (mRNA, inactivated, viral-vectored) are in advanced phases of human clinical trials or recently granted EUAs for immunization of humans, their efficacy in curtailing transmission remains to be established. Based on preclinical data in multiple animal models, we suggest that intranasal delivery of ChAd-SARS-CoV-2-S or possibly other viral-vectored or subunit-based vaccines is a promising platform for preventing SARS-CoV-2 infection, disease, and transmission, and warrants further evaluation in humans.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04324606 Active, not recruiting A Study of a Candidate COVID-19 Vaccine (COV001) Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
